Memantine ameliorates autistic behavior, biochemistry & blood brain barrier impairments in rats

Brain Research Bulletin

Volumn 124, Issue , 2016, Pages 27-39

  Kumar, Hariom ^a   Sharma, Bhupesh ^b,c  

^a BHARAT INSTITUTE OF TECHNOLOGY   (India)

^b AMITY UNIVERSITY   (India)

^c Dilshad Garden   (India)

Author keywords

Autism; Blood brain barrier permeability; Intestinal motility; Mitochondrial complex; NMDA receptor; Serotonin

Indexed keywords

CALCIUM; CATALASE; GLUTATHIONE; MEMANTINE; MITOCHONDRIAL COMPLEX II; MITOCHONDRIAL COMPLEX IV; MYELOPEROXIDASE; NITRATE; NITRITE; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SEROTONIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNCLASSIFIED DRUG; VALPROIC ACID; AMINO ACID RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; AUTISM; BLOOD BIOCHEMISTRY; BLOOD BRAIN BARRIER; BRAIN; BRAIN BIOCHEMISTRY; CALCIUM BLOOD LEVEL; CEREBELLUM; CONTROLLED STUDY; ELEVATED PLUS MAZE TEST; ENZYME ACTIVITY; EXPERIMENTAL SOCIAL BEHAVIOR TEST; EXPLORATORY BEHAVIOR; HOLE BOARD TEST; ILEUM; INFLAMMATION; INTESTINE MOTILITY; LOCOMOTION; NEWBORN; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PREFRONTAL CORTEX; PRENATAL PERIOD; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL; SOCIABILITY; SOCIAL BEHAVIOR; SOCIAL INTERACTION; SOCIAL PREFERENCE; Y-MAZE TEST; ANIMAL; AUTISTIC DISORDER; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; FEMALE; HUMAN RELATION; MALE; MAZE TEST; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; PRENATAL EXPOSURE; WISTAR RAT;

ANIMALS; AUTISTIC DISORDER; BLOOD-BRAIN BARRIER; BRAIN; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; EXPLORATORY BEHAVIOR; FEMALE; INTERPERSONAL RELATIONS; LOCOMOTION; MALE; MAZE LEARNING; MEMANTINE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RATS; RATS, WISTAR; VALPROIC ACID;

EID: 84961730772     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2016.03.013     Document Type: Article

References (69)

1. Abdel-Salam O.M., Salem N.A., Hussein J.S. Effect of aspartame on oxidative stress and monoamine neurotransmitter levels in lipopolysaccharide-treated mice. Neurotox. Res. 2012, 21:245-255.
2. Ahn Y., Narous M., Tobias R., Rho J.M., Mychasiuk R. The ketogenic diet modifies social and metabolic alterations identified in the Pre-VPA model of autism spectrum disorder. Dev. Neurosci. 2014, 36:371-380.
3. Aida T., Yoshida J., Nomura M., Tanimura A., Iino Y., Soma M., Bai N., Ito Y., Cui W., Aizawa H., et al. Astroglial glutamate transporter deficiency increases synaptic excitability and leads to pathological repetitive behaviors in mice. Neuropsychopharmacology 2015, 40:1569-1579.
4. Al-Hazmi M.A., Rawi S.M., Arafa N.M., Wagas A., Montasser A.O. The potent effects of ginseng root extract and memantine on cognitive dysfunction in male albino rats. Toxicol. Ind. Health 2015, 31:494-509.
5. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2013, American Psychiatric Publishing, Arlington, VA. 5th edn.
6. Burket J.A., Benson A.D., Tang A.H., Deutsch S.I. NMDA receptor activation regulates sociability by its effect on mTOR signaling activity. Prog. Neuropsychopharmacol. Biol. Psychiatry 2015, 60:60-65.
7. Burnashev N., Szepetowski P. NMDA receptor subunit mutations in neurodevelopmental disorders. Curr. Opin. Pharmacol. 2015, 20:73-82.
8. Byrge L., Dubois J., Tyszka J.M., Adolphs R., Kennedy D.P. Idiosyncratic brain activation patterns are associated with poor social comprehension in autism. J. Neurosci. 2015, 35:5837-5850.
9. Chauhan A., Gu F., Essa M.M., Wegiel J., Kaur K., Brown W.T., Chauhan V. Brain region-specific deficit in mitochondrial electron transport chain complexes in children with autism. J. Neurochem. 2011, 117:209-220.
10. Chung W., Choi S.Y., Lee E., Park H., Kang J., Park H., Choi Y., Lee D., Park S.G., Kim R., et al. Social deficits in IRSp53 mutant mice improved by NMDAR and mGluR5 suppression. Nat. Neurosci. 2015, 18:435-443.
11. Danysz W., Parsons C.G. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int. J. Geriatr. Psychiatry 2003, 18:S23-S32.
12. De Felice F.G., Velasco P.T., Lambert M.P., Viola K., Fernandez S.J., Ferreira S.T., Klein W.L. A beta oligomers induce neuronal oxidative stress through an N-methyl-d-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. Chem. 2007, 282:11590-11601.
13. de Theije C.G., Koelink P.J., Korte-Bouws G.A., Lopes da Silva S., Korte S.M., Olivier B., Garssen J., Kraneveld A.D. Intestinal inflammation in a murine model of autism spectrum disorders. Brain Behav. Immun. 2014, 37:240-247.
14. El-Ansary A., Al-Ayadhi L. GABAergic/glutamatergic imbalance relative to excessive neuroinflammation in autism spectrum disorders. J. Neuroinflamm. 2014, 11:189.
15. Érces D., Varga G., Fazekas B., Kovács T., Tokés T., Tiszlavicz L., Fülöp F., Vécsei L., Boros M., Kaszaki J. N-Methyl-d-aspartate receptor antagonist therapy suppresses colon motility and inflammatory activation six days after the onset of experimental colitis in rats. Eur. J. Pharmacol. 2013, 691:225-234.
16. Galuska L., Szakáll S., JrEmri M., Oláh R., Varga J., Garai I., Kollár J., Pataki I., Trón L. PET and SPECT scans in autistic children. Orv. Hetil. 2002, 143:1302-1304.
17. Gao Y., Payne R.S., Schurr A., Hougland T., Lord J., Herman L., Lei Z., Banerjee P., El-Mallakh R.S. Memantine reduces mania-like symptoms in animal models. Psychiatry Res. 2011, 188:366-371.
18. Go H.S., Kim K.C., Choi C.S., Jeon S.J., Kwon K.J., Han S.H., Lee J., Cheong J.H., Ryu J.H., Kim C.H., Ko K.H., Shin C.Y. Prenatal exposure to valproic acid increases the neural progenitor cell pool and induces macrocephaly in rat brain via a mechanism involving the GSK-3β/β-catenin pathway. Neuropharmacology 2012, 63(November (6)):1028-1041. [Epub 2012 Jul 27]. 10.1016/j.neuropharm.2012.07.028.
19. Halliwell B., Aruoma O.I., Wasil M., Gutteridge J.M. The resistance of transferrin, lactoferrin and caeruloplasmin to oxidative damage. Biochem. J 1988, 256:311-312.
20. Hodge D., Carollo T.M., Lewin M., Hoffman C.D., Sweeney D.P. Sleep patterns in children with and without autism spectrum disorders: developmental comparisons. Res. Dev. Disabil. 2014, 35:1631-1638.
21. Huang C.Y., Wang L.C., Wang H.K., Pan C.H., Cheng Y.Y., Shan Y.S., Chio C.C., Tsai K.J. Memantine alleviates brain injury and neurobehavioral deficits after experimental subarachnoid hemorrhage. Mol. Neurobiol. 2015, 51(June):1038-1052.
22. Jafarian I., Eskandari M.R., Mashayekhi V., Ahadpour M., Hosseini M.J. Toxicity of valproic acid in isolated rat liver mitochondria. Toxicol. Mech. Methods 2013, 23:617-623.
23. Ju W.K., Kim K.Y., Noh Y.H., Hoshijima M., Lukas T.J., Ellisman M.H., Weinreb R.N., Perkins G.A. Increased mitochondrial fission and volume density by blocking glutamate excitotoxicity protect glaucomatous optic nerve head astrocytes?. Glia 2015, 63(5):736-753.
24. Kamat P.K., Kyles P., Kalani A., Tyagi N. Hydrogen sulfide ameliorates homocysteine-induced Alzheimer's disease-like pathology, blood-brain barrier disruption, and synaptic disorder. Mol. Neurobiol. 2015, (Epub ahead of print).
25. Kang J., Kim E. Suppression of NMDA receptor function in mice prenatally exposed to valproic acid improves social deficits and repetitive behaviors. Front. Mol. Neurosci. 2015, 8:17.
26. Kim K.C., Kim P., Go H.S., Choi C.S., Yang S.I., Cheong J.H., Shin C.Y., Ko K.H. The critical period of valproate exposure to induce autistic symptoms in Sprague-Dawley rats. Toxicol. Lett. 2011, 137-142.
27. Kim J.W., Choi C.S., Kim K.C., Park J.H., Seung H., Joo S.H., Yang S.M., Shin C.Y., Park S.H. GIT abnormalities induced by Pre-VPA exposure in rat offspring. Toxicol. Res. 2013, 29:173-179.
28. Kim K.C., Lee D.K., Go H.S., Kim P., Choi C.S., Kim J.W., Jeon S.J., Song M.R., Shin C.Y. Pax6-dependent cortical glutamatergic neuronal differentiation regulates autism-like behavior in prenatally valproic acid-exposed rat offspring. Mol. Neurobiol. 2014, 49:512-528.
29. Kobata A., Kotani T., Komatsu Y., Amagase K., Kato S., Takeuchi K. Dual action of nitric oxide in the pathogenesis of ischemia/reperfusion-induced mucosal injury in mouse stomach. Digestion 2007, 75:188-197.
30. Kumar H., Sharma B. Minocycline ameliorates prenatal valproic acid induced autistic behaviour, biochemistry and blood-brain barrier impairments in rats. Brain Res. 2016, 1630:83-97. (Epub 2015 Nov 10). 10.1016/j.brainres.2015.10.052.
31. Kumar H., Sharma B.M., Sharma B. Benefits of agomelatine in behavioral, neurochemical and blood-brain barrier alterations in prenatal valproic acid induced autism spectrum disorder. Neurochem. Int. 2015, 91:34-45. 10.1016/j.neuint.2015.10.007.
32. Kysenius K., Brunello C.A., Huttunen H.J. Mitochondria and NMDA receptor-dependent toxicity of berberine sensitizes neurons to glutamate and rotenone injury. PLoS One 2014, 9(9):e107129.
33. Lai M.C., Lombardo M.V., Baron-Cohen S. Autism. Lancet 2014, 383:896-910.
34. Lee E.J., Choi S.Y. NMDA receptor dysfunction in autism spectrum disorders. Curr. Opin. Pharmacol. 2015, 20:8-13.
35. Lipton S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov. 2006, 5:160-170.
36. Liu Y., Wang D., Wang H., Qu Y., Xiao X., Zhu Y. The protective effect of HET0016 on brain edema and blood-brain barrier dysfunction after cerebral ischemia/reperfusion. Brain Res. 2014, 1544:45-53.
37. Lucchina L., Depino A.M. Altered peripheral and central inflammatory responses in a mouse model of autism. Autism Res. 2014, 7:273-289.
38. Manaenko A., Chen H., Kammer J., Zhang J.H., Tang J. Comparison Evans blue injection routes: intravenous versus intraperitoneal, for measurement of blood-brain barrier in a mice hemorrhage model. J. Neurosci. Methods 2011, 195:206-210.
39. Marcinko K., Parsons T., Lerch J.P., Sled J.G., Sakic B. Effects of prolonged treatment with memantine in the MRL model of CNS lupus. Clin. Exp. Neuroimmunol. 2012, 3:116-128.
40. Markram K., Rinaldi T., La Mendola D., Sandi C., Markram H. Abnormal fear conditioning and amygdala processing in an animal model of autism. Neuropsychopharmacology 2008, 33:901-912.
41. Mazurek M.O., Vasa R.A., Kalb L.G., Kanne S.M., Rosenberg D., Keefer A., Murray D.S., Freedman B., Lowery L.A. Anxiety sensory over-responsivity, and gastrointestinal problems in children with autism spectrum disorders. J. Abnorm. Child Psychol. 2013, 41:165-176.
42. Merali Z., Presti-Torres J., Mackay J.C., Johnstone J., Du L., St-Jean A., Levesque D., Kent P., Schwartsmann G., Roesler R., et al. Long-term behavioral effects of neonatal blockade of gastrin-releasing peptide receptors in rats: similarities to autism spectrum disorders. Behav. Brain Res. 2014, 263:60-69.
43. Miller R.D., Monsul N.T., Vender J.R., Lehmann J.C. NMDA- and endothelin-1-induced increases in blood-brain barrier permeability quantitated with Lucifer yellow. J. Neurol. Sci. 1996, 136:37-40.
44. 2+ elevation through the up-regulation of surface transient receptor potential 3 (TRPC3) channels in rodent microglia. J. Biol. Chem. 2014, 289:18549-18555.
45. Nakao A., Miki T., Shoji H., Nishi M., Takeshima H., Miyakawa T., Mori Y. Comprehensive behavioral analysis of voltage-gated calcium channel beta-anchoring and -regulatory protein knockout mice. Front. Behav. Neurosci. 2015, 9:141.
46. Onore C.E., Nordahl C.W., Young G.S., Van de Water J.A., Rogers S.J., Ashwood P. Levels of soluble platelet endothelial cell adhesion molecule-1 and P-selectin are decreased in children with autism spectrum disorder. Biol. Psychiatry 2012, 72:1020-1025.
47. Pietá Dias C., Martins de Lima M.N., Presti-Torres J., Dornelles A., Garcia V.A., SicilianiScalco F., RewsaatGuimarães M., Constantino L., Budni P., et al. Memantine reduces oxidative damage and enhances long-term recognition memory in aged rats. Neuroscience 2007, 146:1719-1725.
48. Rai S., Kamat P.K., Nath C., Shukla R. Glial activation and post-synaptic neurotoxicity: the key events in Streptozotocin (ICV) induced memory impairment in rats. Pharmacol. Biochem. Behav. 2014, 117:104-117.
49. Restall G., Magill-Evans J. Play and preschool children with autism. Am. J. Occup. Ther. 1994, 48(February (2)):113-120.
50. Rinaldi T., Kulangara K., Antoniello K., Markram H. Elevated NMDA receptor levels and enhanced postsynaptic long-term potentiation induced by prenatal exposure to valproic acid. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:13501-13506.
51. Rinaldi T., Silberberg G., Markram H. Hyperconnectivity of local neocortical microcircuitry induced by prenatal exposure to valproic acid. Cereb. Cortex 2008, 4:763-770.
52. Sandhya T., Sowjanya J., Veeresh B. Bacopa monniera (L.) Wettst ameliorates behavioral alterations and oxidative markers in sodium valproate induced autism in rats. Neurochem. Res. 2012, 37(May (5)):1121-1131. [Epub 2012 Feb 10]. 10.1007/s11064-012-0717-1.
53. Schneider T., Przewłocki R. Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology 2005, 30:80-89.
54. Schneider T., Turczak J., Przewłocki R. Environmental enrichment reverses behavioral alterations in rats prenatally exposed to valproic acid: issues for a therapeutic approach in autism. Neuropsychopharmacology 2006, 31:36-46.
55. Simma N., Bose T., Kahlfuß S., Mankiewicz J., Lowinus T., Lühder F., Schüler T., Schraven B., Heine M., Bommhardt U. NMDA-receptor antagonists block B-cell function but foster IL-10 production in BCR/CD40-activated B cells. Cell Commun. Signal. 2014, 12:75.
56. Singh P., Gupta S., Sharma B. Melatonin receptor and KATP channel modulation in experimental vascular dementia. Physiol. Behav. 2015, 142:66-78.
57. Sobaniec-Łotowska M.E., Lotowska J.M. Ultrastructural study of cerebellar dentate nucleus astrocytes in chronic experimental model with valproate. Folia Neuropathol. 2005, 43:166-171.
58. Sobaniec-Lotowska M.E., Sobaniec W. Morphological features of encephalopathy after chronic administration of the antiepileptic drug valproate to rats. A transmission electron microscopic study of capillaries in the cerebellar cortex. Exp. Toxicol. Pathol. 1999, 48:65-75.
59. Spencer D., Marshall J., Post B., Kulakodlu M., Newschaffer C., Dennen T., Azocar F., Jain A. Psychotropic medication use and polypharmacy in children with autism spectrum disorders. Pediatrics 2013, 132:833-840.
60. Stolp H.B., Dziegielewska K.M., Ek C.J., Potter A.M., Saunders N.R. Long-term changes in blood-brain barrier permeability and white matter following prolonged systemic inflammation in early development in the rat. Eur. J. Neurosci. 2005, 22:2805-2816.
61. Suzuki K., Sugihara G., Ouchi Y., Nakamura K., Futatsubashi M., Takebayashi K., Yoshihara Y., Omata K., Matsumoto K., Tsuchiya K.J., et al. Microglial activation in young adults with autism spectrum disorder. JAMA Psychiatry 2013, 70:49-58.
62. Werling D.M., Geschwind D.H. Recurrence rates provide evidence for sex-differential, familial genetic liability for autism spectrum disorders in multiplex families and twins. Mol. Autism 2015, 6:27.
63. Wincott C.M., Kim S., Titcombe R.F., Tukey D.S., Girma H.K., Pick J.E., Devito L.M., Hofmann F., Hoeffer C., Ziff E.B. Spatial memory deficits and motor coordination facilitation in cGMP-dependent protein kinase type II-deficient mice. Neurobiol. Learn Mem. 2013, 99:32-37.
64. Wu H.M., Tzeng N.S., Qian L., Wei S.J., Hu X., Chen S.H., Rawls S.M., Flood P., Hong J.S., Lu R.B. Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropsychopharmacology 2009, 34:2344-2357.
65. Xiao Z., Jaiswal M.K., Deng P.Y., Matsui T., Shin H.S., Porter J.E., Lei S. Requirement of phospholipase C and protein kinase C in cholecystokinin-mediated facilitation of NMDA channel function and anxiety-like behavior. Hippocampus 2012, 22:1438-1450.
66. Yamamoto S., Ohba H., Nishiyama S., Harada N., Kakiuchi T., Tsukada H., Domino E.F. Subanesthetic doses of ketamine transiently decrease serotonin transporter activity: a PET study in conscious monkeys. Neuropsychopharmacology 2013, 38:2666-2674.
67. Yao Y., Walsh W.J., McGinnis W.R., Praticò D. Altered vascular phenotype in autism: correlation with oxidative stress. Arch. Neurol. 2006, 63:1161-1164.
68. Yu J.Y., Zhang B., Peng L., Wu C.H., Cao H., Zhong J.F., Hoffman J., Huang S.H. Repositioning of memantine as a potential novel therapeutic agent against meningitic E. coli-induced pathogenicities through disease-associated alpha7 cholinergic pathway and RNA sequencing-based transcriptome analysis of host inflammatory responses. PLoS One 2015, 10:e0121911. 10.1371/journal.pone.0121911.
69. Zeng X., Asmaro K., Ren C., Gao M., Peng C., Ding J.Y., Fredrickson V., Ji X., Ding Y. Acute ethanol treatment reduces blood-brain barrier dysfunction following ischemia/reperfusion injury. Brain Res. 2012, 1437:127-133.